<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3298">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404611</url>
  </required_header>
  <id_info>
    <org_study_id>DF289III/10IA04</org_study_id>
    <nct_id>NCT01404611</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Media With Tympanostomy Tubes (AOMT) in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a combination of an antibiotic plus a
      corticosteroid is safe and effective in treating middle ear infections in children with ear
      tubes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Cessation of Otorrhea</measure>
    <time_frame>From baseline until the end of the study (up to 22 days)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>DF289</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DF277</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DF289 plus DF277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ear drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF289</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF289</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF277</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF289 plus DF277</intervention_name>
    <description>Ear drops</description>
    <arm_group_label>DF289 plus DF277</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months to 12 years

          -  ear tube in the ear which will be treated

          -  otorrhea for 3 weeks or less

          -  moderate or severe otorrhea

        Exclusion Criteria:

          -  other ear diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratorios SALVAT S.A.</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 22, 2015</lastchanged_date>
  <firstreceived_date>July 22, 2011</firstreceived_date>
  <firstreceived_results_date>July 23, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>with tubes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="P2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="P3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="B2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="B3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
                <measurement group_id="B2" value="108"/>
                <measurement group_id="B3" value="111"/>
                <measurement group_id="B4" value="331"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>randomized patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
                <measurement group_id="B2" value="108"/>
                <measurement group_id="B3" value="111"/>
                <measurement group_id="B4" value="331"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.3" spread="2.4"/>
                <measurement group_id="B2" value="3.2" spread="2.3"/>
                <measurement group_id="B3" value="3.2" spread="2.5"/>
                <measurement group_id="B4" value="3.2" spread="2.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>randomized patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="46"/>
                <measurement group_id="B4" value="138"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="59"/>
                <measurement group_id="B3" value="65"/>
                <measurement group_id="B4" value="193"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Cessation of Otorrhea</title>
        <time_frame>From baseline until the end of the study (up to 22 days)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>DF289</title>
            <description>Ear drops
DF289: Ear drops</description>
          </group>
          <group group_id="O2">
            <title>DF277</title>
            <description>Ear drops
DF277: Ear drops</description>
          </group>
          <group group_id="O3">
            <title>DF289 Plus DF277</title>
            <description>Ear drops
DF289 plus DF277: Ear drops</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="108"/>
                  <measurement group_id="O3" value="111"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Cessation of Otorrhea</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.83" lower_limit="5.49" upper_limit="7.74"/>
                  <measurement group_id="O2" value="22" lower_limit="13.93" upper_limit="22"/>
                  <measurement group_id="O3" value="4.94" lower_limit="3.74" upper_limit="5.52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During all the study (22 days)</time_frame>
      <desc>There were 331 patients randomized in the study, but only 330 patients were dosed. Only dosed patients are considered for the Adverse Event Reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>DF289</title>
          <description>Ear drops
DF289: Ear drops</description>
        </group>
        <group group_id="E2">
          <title>DF277</title>
          <description>Ear drops
DF277: Ear drops</description>
        </group>
        <group group_id="E3">
          <title>DF289 Plus DF277</title>
          <description>Ear drops
DF289 plus DF277: Ear drops</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <description>Only 1 event in the DF289 group and 2 events in the DF277 group were considered related TEAE. The other events were considered non related TEAE</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Non related TEAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Enrique Jimenez, Medical Director</name_or_title>
      <organization>Laboratorios SALVAT</organization>
      <phone>+34933946470</phone>
      <email>ejimenezv@salvatbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
